The global adhesion barrier market size is projected to reach USD 832 million by 2027 from USD 549 million in 2020, at a CAGR of 7.4% during 2021 to 2027. Adhesion barrier is the medical device used to avoid the adhesion occurring during the surgery. Adhesion barrier reduce the abnormal internal scarring by separating organs and internal tissues. The formation of adhesion causes the infertility, chronic pain, and bowel obstruction. These barriers are prepared from natural or synthetic sources and the applications include gynecological, abdominal. Cardiovascular, orthopedic, urological, and reconstructive surgeries. The expansion of this market is being fueled by an increase in the number of surgeries and sports-related injuries, as well as an increase in geriatric population and increased awareness of adhesion formation and adhesion-related disorders. However, due to the COVID-19 pandemic, this market is currently experiencing a slight slowdown in growth due to a decrease in the number of surgical procedures performed to protect patients. However, as the global economy returns to normal, the number of surgical treatments on hold will gradually increase. Despite the concerns, surgeons are hesitant to utilise adhesion barriers due to a lack of/limited solid clinical evidence confirming the safety and efficacy of commercialised adhesion barrier solutions. Companies also have a hard time getting marketing authorization for their products due to concerns about the safety and efficacy of adhesion barriers. In addition, due to poor clinical outcomes, licenced adhesion barrier treatments have been phased out of the market in recent years. New adhesion barriers necessitate significant expenditure, and new products typically take more than 7–8 years to get marketing approval. The cost and time it takes for a product to undergo clinical trials and then pass those studies is quite high, with only a small possibility of the product receiving approval.